<?xml version="1.0" encoding="UTF-8"?>
<p>Arbidol is an antiviral that has been approved in China and Russia for treating influenza, SARS, and Lassa viruses. It blocks virus replication by inhibiting the fusion of the lipid membrane of the virus with the host cells. A study with Arbidol treatment showed it to be possibly superior to LPV/ritonavir in treating COVID-19 because the viral load was undetectable after administration of Arbidol in patients [
 <xref rid="REF50" ref-type="bibr">50</xref>]. (
 <ext-link ext-link-type="uri" xlink:href="ClinicalTrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> identifiers: NCT04273763) [
 <xref rid="REF47" ref-type="bibr">47</xref>].
</p>
